A61K 40/4234
Interleukins [il]
Official title: {Interleukins [IL]}
A61K40/4234 (Interleukins [il]) appears on 69 US grants and 209 published applications in this corpus.
Search patents in A61K- Granted patents
- 69
- Published applications
- 209
- Assignees
- 112
- Inventors
- 466
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 1 |
| 2008 | 2 | 2 |
| 2009 | 1 | 2 |
| 2010 | 1 | 1 |
| 2011 | 1 | 3 |
| 2012 | 2 | 2 |
| 2013 | 2 | 1 |
| 2014 | 3 | 6 |
| 2015 | 1 | 0 |
| 2016 | 3 | 4 |
| 2017 | 0 | 4 |
| 2018 | 4 | 6 |
| 2019 | 4 | 7 |
| 2020 | 3 | 11 |
| 2021 | 4 | 15 |
| 2022 | 4 | 17 |
| 2023 | 8 | 18 |
| 2024 | 7 | 40 |
| 2025 | 12 | 39 |
| 2026 | 6 | 25 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cell immunotherapy for the treatment of cancer14 Jul 2026US 12,678,486 B2Board of Regents, The University of Texas System
- Protein payload release16 Jun 2026US 12,653,839 B2Senti Biosciences, Inc.
- Combination therapy using a chimeric antigen receptor16 Jun 2026US 12,653,850 B2Novartis AG
- Tethered interleukin-15 and interleukin-215 May 2026US 12,617,833 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Therapeutic agents28 Apr 2026US 12,612,445 B2King's College London
- Car-t cells co-expressing cd40l1 Oct 2026US 2026/0294969 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Cell immunotherapy for the treatment of cancer1 Oct 2026US 2026/0295011 A1Board of Regents, The University of Texas System
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Media and methods for differentiating t cells from hematopoietic stem cells17 Sep 2026US 2026/0272984 A1The Regents of the University of California
- Tethered interleukin-15 and interleukin-2117 Sep 2026US 2026/0274917 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
Most cited
By later US patents
- Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells121US 8,822,647 B2City of Hope · 2014
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Chimeric immunoreceptor useful in treating human cancers68US 8,497,118 B2City of Hope · 2013
- Method of inducing memory B cell development and terminal differentiation33US 7,378,276 B2The United States of America as represented by the Department of Health and Human Services · 2008
- Engineered cells expressing multiple immunomodulators and uses thereof19US 9,492,482 B2Intrexon Corporation · 2016